GAIN THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
GAIN THERAPEUTICS INC. - More news...
GAIN THERAPEUTICS INC. - More news...
- Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
- Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
- Gain Therapeutics Announces Oral Presentation at AD/PD 2025
- Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
- Gain Therapeutics To Participate in Upcoming Investor Conferences
- Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
- Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
- Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
- Gain Therapeutics To Present At Biotech Showcase 2025
- Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
- Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
- Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
- Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
- Gain Therapeutics to Participate at Upcoming Investor Conferences
- Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
- Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
- Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
- Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
- Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
- Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
- Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
- Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
- Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
- Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
- Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
- Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
- Gain Therapeutics Announces Proposed Public Offering
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
